Is Axsome Therapeutics, Inc. (AXSM) Among the Best Under-the-Radar Stocks to Invest In?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 10 Best Under-the-Radar Stocks to Invest In.

On July 1, Forbes reported that Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares have doubled over the past nine months. It lifted the company’s market value to $12.6 billion from $6.1 billion after the approval and launch of Auvelity for agitation associated with Alzheimer’s disease. CEO Herriot Tabuteau told Forbes the launch received “tremendous” early reception and raised his peak sales forecast for the Auvelity franchise to $8 billion from $6 billion.

The report said Axsome Therapeutics, Inc. (NASDAQ:AXSM) generated $709 million in revenue over the latest 12 months through the first quarter. It grew by 64% YoY. William Blair analyst Myles Minter projected $975 million in 2026 sales and $1.7 billion in 2027. He said there is a growing demand for the corporation’s daytime sleepiness treatment and multiple late-stage pipeline opportunities. Tabuteau said the biopharmaceutical firm expects to file at least one new drug application annually through 2030. He believes its pipeline could go beyond $20 billion in peak sales.

Is Axsome Therapeutics, Inc. (AXSM) Among the Best Under-the-Radar Stocks to Invest In?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company. It develops therapies for the management of central nervous system disorders.

While we acknowledge the risk and potential of AXSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AXSM and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1